<\/p>\n
Axol Bioscience has secured $2.8 million (around \u00a32.1 million) in funding, part of which will be used to expand its operations in Edinburgh.<\/p>\n
The investment was led by US life sciences specialist BroadOak Capital Partners, with the company\u2019s founding investor, the Roslin Foundation, also participating.<\/p>\n
Axol is a provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research.<\/p>\n
The funding will accelerate Axol\u2019s next phase of growth, supporting the expansion of its US operations and commercial presence.<\/p>\n
It will also enable development of enhanced neuroscience, ophthalmology, and cardiovascular disease models, and cell manufacturing scale-up at its Roslin Innovation Centre base, in response to increasing global customer demand for more human-relevant in vitro disease models.<\/p>\n
Axol Bioscience develops and supplies functional iPSC-derived cells, reagents, and specialist services to pharmaceutical, biotech, CROs and academic institutions worldwide.<\/p>\n
Axol also provides physiologically relevant iPSC-derived models for neurodegenerative disorders including Huntington\u2019s disease and sporadic amyotrophic lateral sclerosis (ALS\/MND).<\/p>\n
Liam Taylor, CEO of Axol Bioscience, said: \u201cWe\u2019re proud to partner with BroadOak, a global leader in life sciences investing.<\/p>\n
\u201cTheir expertise and support, alongside our long-term partner Roslin Foundation, reflects confidence in our long-term vision, team, products, and technology as we scale operations and expand internationally.\u201d<\/p>\n
Oliver Richardson, CFO, added: \u201cFollowing Axol\u2019s 45% revenue growth in 2025 and 36% in 2024, this funding allows us to strengthen our US operations and expand manufacturing capacity at our Edinburgh site, ensuring we can continue to meet increasing global demand.\u201d<\/p>\n
Daniel Friedman, managing director at BroadOak Capital Partners, said: \u201cAxol is a leader in their space and is well positioned as global regulators actively usher in the adoption of cell-based models.<\/p>\n
\u201cWe are excited to be partnering with Liam, Oli, and the entire Axol team to support their next phase of growth.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Axol Bioscience has secured $2.8 million (around \u00a32.1 million) in funding, part of which will be used to…\n","protected":false},"author":2,"featured_media":695613,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8816],"tags":[748,1102,4884,712,16,15],"class_list":{"0":"post-695612","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-edinburgh","8":"tag-britain","9":"tag-edinburgh","10":"tag-great-britain","11":"tag-scotland","12":"tag-uk","13":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115894097529504498","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/695612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=695612"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/695612\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/695613"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=695612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=695612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=695612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}